Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bentley Pharmaceuticals saw its shares rise by around 6% after announcing that it had received 12 marketing approvals in Spain for its generic versions of Forest Laboratories' Celexa, Merck & Co's Proscar and Bristol-Myers Squibb's Pravachol.
Subscribe to our email newsletter
Bentley received approval to market a 30mg generic version of depression drug Celexa (citalopram) in Spain through its wholly-owned subsidiaries, Laboratorios Rimafar and Laboratorios Davur, and a branded-generic version of the 30mg dosage level of citalopram through its Laboratorios Belmac subsidiary. The branded version is marketed under the Belmac trade name Somac.
Bentley also received approval to market a 5mg generic version of Proscar (finasteride) in Spain through Belmac, Davur and Rimafar. Finasteride belongs to a class of type II 5 alpha-reductase inhibitors used in the treatment of enlarged prostate glands. In addition, Laboratorios Rimafar and Laboratorios Belmac each received approvals to market generic-equivalent and branded versions of pravastatin in 10mg, 20mg and 40mg tablets.
Finally, Bentley received approvals for a generic version of heart drug Pravachol (pravastatin) in 10mg, 20mg, 40mg and 80mg dosage levels, for which Laboratorios Davur gained marketing rights in October 2005.
“These approvals strengthen our portfolio and underscore our success in advancing our pipeline, both in Spain and in other European countries,” noted John Sedor, Bentley’s president. “These latest approvals follow the 51 we received over the past 12 months, including 30 approvals in Spain and 21 in other EU countries.”